

Methodology of Celgene s.r.o. for disclosing Transfers of Value to Health Care Professionals and Health Care Organisations in accordance with the AIFP Code of Conduct (in accordance with EFPIA Disclosure Code)

Disclosure applies to all direct and indirect Transfers of Value to any Recipient who is a Healthcare Professional or a Healthcare Organisation.

Transfers of Value subject to disclosure under the Act No. 362/2011 Coll., on medicinal products and medical devices, as amended, that have been reported for 2020 at http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach do not fall under the present report.

The 2020 report under AIFP Code of Conduct shall only include those Transfers of Value for the year 2020 (1.1.2020-31.12.2020) that have not been disclosed, as a result of differences between the EFPIA definition and local legislation. Hence, the following three categories are relevant for 2020 report under AIFP Code of Conduct:

- Scientific HCO on individual basis (scientific HCO = Non healthcare service providers, who are not the third parties and are end-recipients of the value and the value is not otherwise disclosed in the NCZI report);
- Cross-border transfer of values to non-R&D providers - individually if consent to disclosure was secured, otherwise in aggregate;
- R&D – in aggregate if the publication does not fall into the NCZI reporting irrespective of the start date of the study.

A transfer falls within the above period depending on its effective day, namely the day of payment in case of monetary transfers and the day of performance in case of transfers in kind.

Monetary transfers are disclosed as net payments less tax paid.

30.6.2021